Yissum - Research Development Company of the Hebrew University

Treatment of Genetic Diseases Caused by Nonsense Mutation

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Treatment of Genetic Diseases Caused by Nonsense Mutation
Project ID : 6-2018-4579

Description of the technology

Categories:

Life sciences & Biotechnology

Technology Keywords:

Muscular dystrophy, nonsense mutation,

Duchenne, Becker, cystic fibrosis, genetic diseases, dystrophin

Development Stage:

Proof of concept in lab environment

Patent Status:

Provisional patent in preparation

Market

Nonsense mutation are the cause of many genetic diseases, such as Duchenne/Backer and CF.

The global Duchenne treatment market is expected to reach $990 million by 2019. The global CF therapeutics market size was estimated at USD 3.5 billion in 2016 and is expected to grow at a CAGR of 16.7% from 2017 to 2025.

Our Innovation

A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein, such as dystrophin in Duchenne muscular dystrophy. Nonsense mutations caused by premature stop codon, are treated using read-through therapies that are only partially efficient since they rely on the existence of mutant mRNA which is unstable.

The proposed invention is anovel target for the treatment of genetic diseases caused by nonsense mutations, which increases the success of current read through therapies, and may serve as a stand-alone treatment in cases that premature stop codon is not involved but the mRNA is unstable for other reasons.

Highlights

  • Novel target with several proposed small molecules to inhibit this target (repositioning of existing drugs)
  • since the compounds are small molecules, they are stable, dosage-regulated, and have increased penetration to all body tissues – advantage in Duchenne delivery to muscles, and CF delivery to the lungs.
  • In-vitro results using cells derived from Duchene and Becker patients show increased mRNA stability.

The Opportunity

  • Nonsense mutation are the cause of many genetic diseases, such as Duchenne/Becker, Cystic fibrosis and others. Despite rapid developments over the last years, there remains a large unmet need among patients who are not amenable to mutation-specific drugs.
  • Duchenne, Becker and CF are rare diseases and considered orphan diseases by the FDA with an accelerated regulatory path.
  • Existing read-through drugs have poor effectiveness. The technology suggests increased effectiveness and relief of Duchenne symptoms.
  • This technology is applicable for other genes and not limited to Dystrophin (Becker and Duchenne target) or CFTR (Cystic fibrosis).
  • The team has the capabilities to advance the technology up to pre-clinical studies.

Development Milestones

Preliminary results to support the core of the invention were obtained in patient-derived cells.

Next steps are in-vivo studies

Figure 1. A general scheme of nonsense mutation causing mRNA degradation and mRNA stabilization by targeted drugs.

Project manager

Shimrit Frenkel
Licensing Agriculture

Project researchers

Rotem Karni
HUJI, School of Medicine - IMRIC
Biochemistry and Molecular Biology

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.